Last reviewed 2026-04-23 · How we verify

Ocrevus-EU

Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis.

Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis. Used for Relapsing-remitting multiple sclerosis (RRMS), Primary progressive multiple sclerosis (PPMS).

At a glance

Mechanism of action

Ocrevus (ocrelizumab) targets CD20, a surface antigen on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct cell death. By reducing B cell populations, it decreases the production of autoantibodies and pro-inflammatory cytokines that drive multiple sclerosis pathology. This mechanism helps reduce relapse rates and slow disability progression in both relapsing and primary progressive MS.

Approved indications

• Relapsing-remitting multiple sclerosis (RRMS)
• Primary progressive multiple sclerosis (PPMS)

Common side effects

• Infusion reactions
• Upper respiratory tract infections
• Lower respiratory tract infections
• Headache
• Fatigue
• Herpes zoster

Key clinical trials

• Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (PHASE3)
• Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (PHASE3)
• A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.